The reasons for the differences in CD62P between direct ex vivo analysis of platelets from COVID-19 patients and induction of healthy platelet activation from plasma from COVID-19 patients may reflect a different kinetics after in vivo versus in vitro activation, or non-plasma-based activation signals for CD62P, such as those that occur when platelets interact with collagen in a damaged vessel wall. This evidence concerns the gene SELP and COVID-19.